Abstract

BackgroundOxidative stress and inflammatory factors are deeply involved in progression of atherosclerosis. Mitochondrion-targeted peptide SS-31, selectively targeting to mitochondrial inner membrane reacting with cardiolipin, has been reported to inhibit ROS generation and mitigate inflammation. The present study was designed to investigate whether SS-31 could suppress the development of atherosclerosis in vivo.MethodsMale ApoE-/- mice (8 weeks old) fed with Western diet were treated with normal saline or SS-31 (1 mg/kg/d or 3 mg/kg/d) through subcutaneous injection for 12 weeks. Oil Red O staining was performed to evaluate area and sizes of the plaques. DHE staining and immunohistochemical staining of 8-OHDG was performed to assess the oxidative stress. The aorta ATP contents were assessed by the ATP bioluminescence assay kit. Immunohistochemical staining of CD68 and α-SMA and Masson’s trichrome staining were performed to evaluate the composition of atherosclerotic plaque. Biochemical assays were performed to determine the protein level and activity of superoxide dismutase (SOD). The levels of CD36, LOX-1 and ABCA1 were immunohistochemically and biochemically determined to evaluate the cholesterol transport in aorta and peritoneal macrophages. Inflammatory factors, including ICAM-1, MCP-1, IL-6 and CRP in serum, were detected through ELISA.ResultsSS-31 administration reduced the area and sizes of western diet-induced atherosclerotic plaques and changed the composition of the plaques in ApoE-/- mice. Oxidative stress was suppressed, as evidenced by the reduced DHE stain, down-regulated 8-OHDG expression, and increased SOD activity after chronic SS-31 administration. Moreover, systemic inflammation was ameliorated as seen by decreasing serum ICAM-1, MCP-1, and IL-6 levels. Most importantly, SS-31 administration inhibited cholesterol influx by down-regulating expression of CD36 and LOX-1 to prevent lipid accumulation to further suppress the foam cell formation and atherosclerotic progression.ConclusionAdministration of SS-31 prevents against atherosclerotic formation in ApoE-/- mice suggesting that SS-31 might be considered to be a potential drug to prevent atherosclerotic progression.

Highlights

  • Atherosclerosis, the main contributor to cardiovascular mortality, is a degenerative disease associated with oxidative stress and inflammatory factors [1]

  • Systemic inflammation was ameliorated as seen by decreasing serum intracellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, and IL-6 levels

  • Administration of SS-31 prevents against atherosclerotic formation in ApoE-/- mice suggesting that SS-31 might be considered to be a potential drug to prevent atherosclerotic progression

Read more

Summary

Introduction

Atherosclerosis, the main contributor to cardiovascular mortality, is a degenerative disease associated with oxidative stress and inflammatory factors [1]. Lipid accumulation within macrophages leading to foam cell formation and necrotic core growth accelerates atherosclerosis [3]. Limiting lipid retention and increasing lipid efflux in macrophages are promising strategy to prevent foam cell formation and atherosclerosis [4]. Oxidative stress probably due to the combination of highly reactive oxygen species (ROS) generation and impaired antioxidant defense is deeply involved in the pathogenesis of atherosclerosis [5]. ROS can modulate atherosclerosis progression partially by promoting DNA damage and accelerating cellular senescence. Oxidative stress and inflammatory factors are deeply involved in progression of atherosclerosis. The present study was designed to investigate whether SS-31 could suppress the development of atherosclerosis in vivo

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.